Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
NCT03617172 · Vanderbilt University Medical Center · PHASE2 · terminated · last registry update 2022-11-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low enrollment” | – | Registry record, Vanderbilt University Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGER3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-07Also stopped (terminated): MemorialCare Health System, Misoprostol (NCT00514618)
- 2023-10-30Also stopped (terminated): Bnai Zion Medical Center, Misoprostol Oral Tablet (NCT03866772)
- 2023-10-23Results posted on the registry: MemorialCare Health System, Misoprostol (NCT00514618)
- 2023-10-12Phase 3 first posted: Stanford University, Misoprostol 400mcg buccal + Placebo (NCT06078501)
- 2023-09-28Also stopped (withdrawn): Montefiore Medical Center, Misoprostol (NCT04768010)
- 2023-09-15Also stopped (suspended): Guangzhou Women and Children's Medical Center, Induction of labor with PGE2 (NCT04780269)
- 2023-09-07Results posted on the registry: Northwestern University, Misoprostol + Placebo (NCT02209545)
- 2023-09-07Also stopped (terminated): Northwestern University, Misoprostol + Placebo (NCT02209545)
- 2023-07-25Also stopped (terminated): Gynuity Health Projects, Mifepristone + 2 doses of misoprostol 800 mcg (NCT05119439)
- 2023-07-24Phase 3 first posted: Services Institute of Medical Sciences, Pakistan, Misoprostol Oral Tablet + vaginal misoprostol (NCT05957666)
- 2023-06-28Results posted on the registry: University of North Carolina, Chapel Hill, Ulipristal Acetate Tablets + Misoprostol Pill (NCT05216952)
- 2023-05-15Also stopped (terminated): University Hospital, Toulouse, Balloon catheter + oral misoprostol + Oral misoprostol alone (NCT03435458)
- 2023-05-03Phase 3 first posted: Planned Parenthood League of Massachusetts, Mifepristone plus one dose Misoprostol + Mifepristone plus two doses Misoprostol (NCT05839899)
- 2023-03-17Phase 3 first posted: Hospital Universitario 12 de Octubre, Vaginal dinoprostone (NCT05774236)
- 2023-03-09Phase 3 first posted: Beni-Suef University, Dinoprostone + Misoprostol (NCT05761418)
- 2023-01-23Results posted on the registry: Boston Medical Center, Methadone Pill + Ibuprofen (NCT04941443)
- 2023-01-23Also stopped (terminated): Boston Medical Center, Methadone Pill + Ibuprofen (NCT04941443)
- 2022-11-14Also stopped (terminated): South Warwickshire NHS Foundation Trust, 10 mg Dinoprostone; CTS, UK + 3 mg Dinoprostone vaginal tablet; Pfizer, UK (NCT02956785)
- 2022-10-13Results posted on the registry: Milton S. Hershey Medical Center, Misoprostol (NCT02777190)
- 2022-10-13Also stopped (terminated): Milton S. Hershey Medical Center, Misoprostol (NCT02777190)
- 2022-06-21Phase 3 first posted: Karolinska Institutet, Misoprostol (NCT05424445)
- 2022-03-31Phase 3 first posted: Calcutta National Medical College and Hospital, Mifepristone + Letrozole (NCT05304273)
- 2022-03-22Also stopped (withdrawn): University of Maryland, Baltimore, Misoprostol (NCT03796416)
- 2022-03-02Results posted on the registry: Medstar Health Research Institute, Mifepristone + Misoprostol (NCT02412618)
- 2022-02-17Phase 3 first posted: Stony Brook University, Sublingual Misoprostol + IV Oxytocin (NCT05245227)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision